Healthcare Professionals’ Perceptions and Clinical Experience with IBUCAP NIGHT for Pain-Associated Sleep Disturbances: A Cross-Sectional Survey in Angola

Introduction: Pain-induced sleep disturbances significantly impact quality of life. To address this, IBUCAP NIGHT, containing Ibuprofen 200 mg and Diphenhydramine Citrate 38 mg, offers a dual-action approach for pain relief and improving sleep. To address the limited real-world evidence regarding clinician experience with IBUCAP NIGHT in Angola, this Healthcare Professional Experience Research (HPER) survey was undertaken. The primary objective of this survey was to evaluate healthcare professionals’ perceptions of the utilization, effectiveness, tolerability, and prescribing practices of IBUCAP NIGHT for the management of pain-associated sleep disturbances in routine clinical practice in Angola. Methodology: A descriptive cross-sectional HPER survey was conducted among 29 participating clinicians in Angola using a structured 20-item questionnaire. Results: Clinicians reported a median patient load of 175 per month, with 10% suffering from pain-induced sleeplessness. The most common sleep disturbances were difficulty in falling asleep (75.9%), inability to stay asleep (65.5%) & frequent awakenings (44.8%). Majority of these patients had acute dental pain (75.9%) and chronic back pain (65.5%). 75.9% responding physicians deemed two capsules as the optimal dose & 62.1% recommended treatment for less than one week. Side effects were mild, with drowsiness being the most frequent (82.8%). Clinicians rated the overall efficacy of IBUCAP NIGHT as “good to excellent” (89.6%), and 89.7% believed it effectively addressed the dual concerns of pain and sleeplessness. Conclusion: Participating clinicians perceived IBUCAP NIGHT as effective/or may improve pain management while also improving sleep quality, with most reporting favorable impressions of patients’ quality of life. These findings reflect clinician-reported perceptions rather than direct patient outcome assessment.